Hodgkin’s Lymphoma Therapeutics - Pipeline Analysis 2018

Hodgkin’s Lymphoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS10927
Available Format:

The Hodgkin’s lymphoma therapeutics pipeline is expected to witness considerable growth in the coming years as the researchers are making novel drug delivery system for the treatment for cancer. The government agencies such as National Cancer Institute and American Cancer Society are supporting the growth of the Hodgkin’s lymphoma (HL) therapeutics pipeline by providing funding, designations and grants for speeding up the drug development process. High prevalence of cancer, increasing awareness regarding cancer treatment, technological advancements and high demand for safe and effective medication are driving the growth of the Hodgkin’s Lymphoma therapeutics pipeline.

Hodgkin lymphoma (HL) or Hodgkin’s disease is an uncommon cancer of the lymphatic system, such as lymph nodes. The lymphatic system is made up of a network of vessels and glands that spread throughout the body. The vessels of lymphatic system known as lymphocytes carrying clear fluid known as lymph, contains lymphocytes (white blood cells that help combat infection). The lymphatic is a part of the human body’s immune system. In Hodgkin’s lymphoma, the patient experiences a painless swelling in a lymph node, usually in the neck, armpit or groin.

Ono Pharmaceuticals and Bristol-Myers Squibb are in the process of developing Opdivo for the treatment of Hodgkin’s disease. Seattle Genetics has developed ADCETRIS (brentuximab vedotin) as an antibody drug conjugate for Hodgkin’s disease. Merck & Co., Inc. has also developed Keytruda for the treatment of Hodgkin’s lymphoma. Though, major companies are developing promising drugs for Hodgkin’s lymphoma treatment, the new entrants are facing the challenge of fulfilling the relapsed or refractory (R/R) Hodgkin’s lymphoma patients’ unmet needs, and of bringing a reduction in the adverse effects of current treatments in the long term, thereby improving patients’ overall survival.

Chemotherapy is used as a conventional therapy for Hodgkin’s lymphoma. The chemotherapy drugs include but are not limited to, Vinblastine, Vincristine, Dacarbazine, Doxorubicin, Chlorambucil, Cyclophosphamide, Cisplatin, Cytarabine, Procarbazine, Prednisolone, Bleomycin, Mustine, Etoposide and Gemcitabine. Nevertheless, immunotherapy, combination therapy, monoclonal antibodies and steroids are also offering effective results for the treatment of Hodgkin’s lymphoma. For further development in the research and development of Hodgkin’s lymphoma, many pharmaceutical companies are entering into partnership contracts. Also, increasing awareness about the treatment and growing occurrence of the disease are acting as driving factors for the pipeline growth. On the contrary, high cost of Hodgkin’s lymphoma treatment, side effects related to the treatment, and high cost incurred by research and development of Hodgkin’s lymphoma drugs are acting as key restraints for the growth of the Hodgkin’s lymphoma drug therapeutics pipeline.

Pharmaceutical companies, such as Mirati Therapeutics, Inc., are developing Mocetinostat in combination with Brentuximab Vedotin in Phase I/II stage for Hodgkin’s lymphoma. Mocetinostat is an orally bioavailable and spectrum-selective Histone Deacetylase (HDAC) inhibitors. The drug candidate is believed to reverse aberrant acetylation resulting from histone acetyltransferase (HAT) mutations, thereby prohibiting tumor progression and reducing tumor burden in patients.

According to the National Cancer Institute, a part of the U.S. National Institutes of Health, an estimated 8,500 new cases and 1,120 deaths were reported in the U.S., in 2016, due to Hodgkin’s lymphoma.

Some of the companies having a pipeline of Hodgkin’s lymphoma therapeutics include Bristol-Myers Squibb Co., Merck & Co. Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Affimed Therapeutics AG, Aeterna Zentaris Inc., Incyte Corporation, and 4SC AG.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry